作者
Spyridon G Deftereos, Frans J Beerkens, Binita Shah, George Giannopoulos, Dimitrios A Vrachatis, Sotiria G Giotaki, Gerasimos Siasos, Johny Nicolas, Clare Arnott, Sanjay Patel, Mark Parsons, Jean-Claude Tardif, Jason C Kovacic, George D Dangas
发表日期
2022/1/4
来源
Circulation
卷号
145
期号
1
页码范围
61-78
出版商
Lippincott Williams & Wilkins
简介
Inflammation plays a prominent role in the development of atherosclerosis and other cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular outcomes. For years, colchicine has been used as a safe and well-tolerated agent in diseases such as gout and familial Mediterranean fever. The widely available therapeutic has several anti-inflammatory effects, however, that have proven effective in a broad spectrum of cardiovascular diseases as well. It is considered standard-of-care therapy for pericarditis, and several clinical trials have evaluated its role in postoperative and postablation atrial fibrillation, postpericardiotomy syndrome, coronary artery disease, percutaneous coronary interventions, and cerebrovascular disease. We aim to summarize colchicine’s pharmacodynamics and the mechanism behind its anti-inflammatory effect, outline thus far accumulated evidence on treatment with …
引用总数
学术搜索中的文章
SG Deftereos, FJ Beerkens, B Shah, G Giannopoulos… - Circulation, 2022